Table 2.
The associations between subsequent therapy (oral, IV BP) and no subsequent treatment with absolute change (g/cm2) in LS, FN, and TH BMD between last denosumab injection (DXA2) and follow-up (DXA3)
| Parameters | Treatment | Mean absolute change (95% confidence interval) |
p valuea |
|---|---|---|---|
| LS BMD Change (g/cm2) |
No treatment (n = 29) Risedronate (n = 20) Alendronate (n = 28) Zoledronic acid (n = 27) |
− 0.041 (− 0.062 to − 0.021) − 0.035 (− 0.052 to − 0.017) − 0.005 (− 0.020 to 0.009) − 0.009 (− 0.025 to 0.008) |
Reference > 0.999 0.015 0.037 |
| FN BMD change (g/cm2) |
No treatment (n = 31) Risedronate (n = 20) Alendronate (n = 34) Zoledronic acid (n = 31) |
− 0.013 (− 0.023 to − 0.003) − 0.011 (− 0.029 to 0.006) 0.004 (− 0.007 to 0.014) 0.004 (− 0.006 to 0.013) |
Reference > 0.999 0.160 0.181 |
| TH BMD change (g/cm2) |
No treatment (n = 31) Risedronate (n = 20) Alendronate (n = 34) Zoledronic acid (n = 31) |
− 0.016 (− 0.025 to − 0.007) − 0.017 (− 0.027 to − 0.007) − 0.006 (− 0.017 to 0.004) 0.001 (− 0.006 to 0.008) |
Reference > 0.999 0.673 0.034 |
IV, intravenous; BP, bisphosphonates; BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; LS, lumbar spine; FN, femoral neck; TH, total hip; ALN, alendronate; ZOL, zoledronic acid
Significant p values are shown in bold
aGroup comparison by analysis of variance (ANOVA): LS (p = 0.004); FN (p = 0.047); TH (p = 0.016). Adjusted p value was calculated from post hoc analysis with the Bonferroni method